These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18200508)

  • 1. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.
    Fishburn CS
    J Pharm Sci; 2008 Oct; 97(10):4167-83. PubMed ID: 18200508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literature.
    Becker R; Dembek C; White LA; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):775-93. PubMed ID: 23252359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEGylated recombinant human interferon-ω as a long-acting antiviral agent: structure, antiviral activity and pharmacokinetics.
    Yu W; Yu C; Wu L; Fang T; Qiu R; Zhang J; Yu T; Fu L; Chen W; Hu T
    Antiviral Res; 2014 Aug; 108():142-7. PubMed ID: 24936771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.
    Yang Z; Wang J; Lu Q; Xu J; Kobayashi Y; Takakura T; Takimoto A; Yoshioka T; Lian C; Chen C; Zhang D; Zhang Y; Li S; Sun X; Tan Y; Yagi S; Frenkel EP; Hoffman RM
    Cancer Res; 2004 Sep; 64(18):6673-8. PubMed ID: 15374983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a.
    Hu X; Olivier K; Polack E; Crossman M; Zokowski K; Gronke RS; Parker S; Li Z; Nestorov I; Baker DP; Clarke J; Subramanyam M
    J Pharmacol Exp Ther; 2011 Sep; 338(3):984-96. PubMed ID: 21690216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEG - a versatile conjugating ligand for drugs and drug delivery systems.
    Kolate A; Baradia D; Patil S; Vhora I; Kore G; Misra A
    J Control Release; 2014 Oct; 192():67-81. PubMed ID: 24997275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
    Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the future of PEGylated therapies?
    Swierczewska M; Lee KC; Lee S
    Expert Opin Emerg Drugs; 2015; 20(4):531-6. PubMed ID: 26583759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse.
    McSweeney MD; Wessler T; Price LSL; Ciociola EC; Herity LB; Piscitelli JA; Zamboni WC; Forest MG; Cao Y; Lai SK
    J Control Release; 2018 Aug; 284():171-178. PubMed ID: 29879519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenyl amide linker improves the pharmacokinetics and pharmacodynamics of N-terminally mono-PEGylated human growth hormone.
    Wu L; Ji S; Shen L; Hu T
    Mol Pharm; 2014 Sep; 11(9):3080-9. PubMed ID: 25115329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein carboxyl amidation increases the potential extent of protein polyethylene glycol conjugation.
    Li S; Yang Z; Sun X; Tan Y; Yagi S; Hoffman RM
    Anal Biochem; 2004 Jul; 330(2):264-71. PubMed ID: 15203332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and analysis of a polyethelene glycol-modified (PEGylated) small molecule inhibitor of integrin {alpha}4{beta}1 with improved pharmaceutical properties.
    Pepinsky RB; Lee WC; Cornebise M; Gill A; Wortham K; Chen LL; Leone DR; Giza K; Dolinski BM; Perper S; Nickerson-Nutter C; Lepage D; Chakraborty A; Whalley ET; Petter RC; Adams SP; Lobb RR; Scott DM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):742-50. PubMed ID: 15485895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEGylation of therapeutic proteins.
    Jevsevar S; Kunstelj M; Porekar VG
    Biotechnol J; 2010 Jan; 5(1):113-28. PubMed ID: 20069580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGylation and its impact on the design of new protein-based medicines.
    Ginn C; Khalili H; Lever R; Brocchini S
    Future Med Chem; 2014; 6(16):1829-46. PubMed ID: 25407370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noncovalent PEGylation, An Innovative Subchapter in the Field of Protein Modification.
    Reichert C; Borchard G
    J Pharm Sci; 2016 Feb; 105(2):386-390. PubMed ID: 26523632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/pharmacodynamic (PK/PD) differentiation of native and PEGylated recombinant human growth hormone (rhGH and PEG-rhGH) in the rat model of osteoarthritis.
    Nemirovskiy O; Zheng YJ; Tung D; Korniski B; Settle S; Skepner A; Yates M; Aggarwal P; Sunyer T; Aguiar DJ
    Xenobiotica; 2010 Aug; 40(8):586-92. PubMed ID: 20509748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic protein-polymer conjugates: advancing beyond PEGylation.
    Pelegri-O'Day EM; Lin EW; Maynard HD
    J Am Chem Soc; 2014 Oct; 136(41):14323-32. PubMed ID: 25216406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation.
    Sun X; Yang Z; Li S; Tan Y; Zhang N; Wang X; Yagi S; Yoshioka T; Takimoto A; Mitsushima K; Suginaka A; Frenkel EP; Hoffman RM
    Cancer Res; 2003 Dec; 63(23):8377-83. PubMed ID: 14678999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.
    Ivens IA; Baumann A; McDonald TA; Humphries TJ; Michaels LA; Mathew P
    Haemophilia; 2013 Jan; 19(1):11-20. PubMed ID: 22913770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging PEGylated drugs.
    Kang JS; Deluca PP; Lee KC
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):363-80. PubMed ID: 19453284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.